Recent studies have also shown that EMP3 is associated with a good survival rate during breast cancer progression, negatively regulates the S phase of the breast cancer cell cycle, inhibits BRCA1 and RAD51 expression after repair of DNA double-strand breaks, interferes with DNA replication and damage repair and stem cell-like characteristics of breast cancer cells, blocks Akt-mTOR signal activation of autophagy, and enhance the sensitivity of breast cells to adriamycin [131]. Here, EMP3 is linked to breast cancer.